MedTrace Logo

Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer

NCT00804830 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2018-08-28

No results posted yet for this study

Summary

Anaplastic Thyroid Cancer is a very aggressive disease. The investigators believe that angiogenesis is very important for these tumors to progress. Preclinical data is suggesting this. This is why we we prospectively want to treat these patients with avastin (and doxorubicin). However, local control is of major concern. Therefore, patients are initially treated with hyperfractionated radiotherapy and undergo surgery. Then they can enter this study.

Conditions

Interventions

DRUG

Bevacizumab

Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w

Sponsors & Collaborators

  • Region Skane

    lead OTHER

Principal Investigators

  • Jan Tennvall, MD, PhD · Dep of Oncology, Lund University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2012-12-31
Completion
2014-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00804830 on ClinicalTrials.gov